関連する実験動画
Updated: Jan 6, 2026
01:19
Mitral Valve Prolapse III: Nursing Management
Published on: June 19, 2025
252
血管新生の非侵襲的評価は,アルファ ((v)) -インテグリンを標的とした超音波とマイクロバブルによるものです
Howard Leong-Poi1, Jonathan Christiansen, Alexander L Klibanov
1Cardiovascular Imaging Center, Cardiovascular Division, University of Virginia, Charlottesville 22908, USA.
Circulation
|January 29, 2003
まとめ
ターゲット化されたマイクロバブルを持つコントラスト強化超音波 (CEU) は,新しい血管の形成を非侵襲的にイメージすることができます. この方法は,アルファ ((v) -インテグリンを発現する新血管を視覚化することによって,治療的血管新生を評価する有望なことを示しています.
科学分野:
- バイオメディカルイメージング
- 血管生物学 血管生物学
- 超音波技術について
背景:
- アンジオゲネシス中の新血管形成を特徴付けるための非侵襲的な方法は不足しています.
- 血管新生は,様々な生理学的および病理学的プロセスにおいて極めて重要です.
- 標的型分子イメージングは,診断能力を向上させる可能性を秘めています.
研究 の 目的:
- 血管新生を画像化するためにアルファ ((v)) -インテグリンを標的としたマイクロバブルを使用してコントラスト強化超音波 (CEU) を開発および評価する.
- 新血管系における標的微小泡の保持と結合を評価する.
- CEUが新血管形成をin vivoで定量化できるかどうかを判断する.
主な方法:
- エキスタチン (MB(E)) または抗アルファ ((v)) 抗体 (MB(アルファ)) を使用してアルファ ((v)) インテグリンを標的としたマイクロバブルの準備.
- 腸内顕微鏡を用いたマウスのクレマスター筋肉におけるマイクロバブルの行動の評価.
- CEUを用いたFGF-2誘発マトリゲルプラグにおける新血管化のインビボ画像化.
主要な成果:
- 標的微泡 (MB(E) とMB(alpha)) は,対照微泡 (MB(c)) と比較して,微血管保持量が著しく増加した.
- マイクロ血管内皮表面に付着した保持された標的型マイクロバブル.
- CEUは,ターゲット化されたマイクロバブルでより高い音響強度を示し,新血管の血液量と良好な相関関係を示しました.
結論:
- アルファ ((v)) インテグリン標的微小泡を用いたCEUは,血管新生を画像化するための非侵襲的な方法である.
- このアプローチは,治療目的の血管新生の評価を可能にします.
- このテクニックは,新血管化の定量的な測定を提供します.
関連する概念動画
Mitral Valve Prolapse III: Nursing Management
252
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
252
Cancer Vaccines
917
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
917
Development of Immunocompetence
759
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
759
Vaccinations
51.1K
Overview
51.1K
Healthcare Associated Infections II: Preventive Measures
3.5K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
Teratogenicity
3.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K